|
KMID : 0882420070720060625
|
|
Korean Journal of Medicine
2007 Volume.72 No. 6 p.625 ~ p.631
|
|
|
Efficacy of administration of weekly docetaxel combined with platinum as a first-line treatment for patients with advanced non-small cell lung cancer
|
|
Kim So-Yeon
Ryoo Hun-Mo
Bae Sung-Hwa
Jung Hyun-Young
Kim Kyung-Chan
Hyun Dae-Sung
Lee Sang-Chae
Kim Kyeong-Ok
Lee Kyoung-Hee
Hyun Myung-Soo
Kwon Young-Lan
Kim Ga-Young
Kim Kyu-Young
Jung Chi-Young
Kim Yeon-Jae
Lee Byung-Ki
Lee Jung-Lim
Lee Won-Sik
|
|
|
Abstract
|
|
|
Backgroudn: Docetaxel is a highly effective chemotherapeutic agent with proven efficacy for non-small cell lung cancer (NSCLC). However, myelosuppression can be a substantial concern when docetaxel is administered every 3 weeks. Weekly administration of low-dose docetaxel has demonstrated a comparable efficacy together with a distinct toxicity profile with reduced myelosuppression. We conducted a phase II study of weekly administration of docetaxel and cisplatin or carboplatin in patients with advanced NSCLC to evaluate efficacy and safety.
Methods:Twenty-nine patients with advanced or metastatic NSCLC who had not received prior treatment were enrolled in the study. The patients received intravenous infusions of docetaxel (35 mg/m2 on days 1, 8, 15) and cisplatin (75 mg/m2 on day 1) or carboplatin (AUC 6), followed by a week of rest.
Results:Twenty-six patients were assessable for efficacy and all patients were assessable for toxicity determination. The overall response rate of the regimen was 44.8%. The median survival was 11.3 months, and the 1-year survival rate was 37%. Of the hematologic toxicities, grade 3/4 neutropenia were observed in 12.6% of the patients, but there were no episodes of neutropenic fever. Non-hematologic toxicities were mild.
Conclusions:With this weekly dosing regimen, although efficacy is comparable, myelosuppression is substantially less, and the overall tolerability profile is better than with dosing every 3 weeks.
|
|
|
KEYWORD
|
|
|
Weekly dosing, Dcisplation, Carboplatin, Non-small cell lung Cancer
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
  
|